Merck & Co. Inc. announced positive results from its Phase 3 KEYNOTE-B96 trial, evaluating the efficacy of KEYTRUDA® (pembrolizumab) in combination with chemotherapy for treating platinum-resistant recurrent ovarian cancer. The study met its primary endpoint, demonstrating a statistically significant improvement in progression-free survival $(PFS)$ for patients with PD-L1-expressing tumors and across all participants. Furthermore, a secondary endpoint of overall survival $(OS)$ was achieved in patients whose tumors express PD-L1. This marks the first time an immune checkpoint inhibitor-based regimen has shown an OS benefit in ovarian cancer. The safety profile of KEYTRUDA was consistent with previous studies, with no new safety signals identified. Results will be shared with regulatory authorities and presented at an upcoming medical meeting.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.